Xenid 1%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xenid 1%

Property Description
Active ingredient Diclofenac (at 1% concentration)
Form Gel (Topical preparation)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Common use Localized Anti-inflammatory and Analgesic
Origin Synthetic

What Pharmacological Class Does Xenid 1% Belong To?

Xenid 1% is a topical preparation classified as a Non-steroidal Anti-inflammatory Drug (NSAID), a pharmacological category recognized globally for treating inflammation and pain. The medication's core identity is defined by its active ingredient, diclofenac, a synthetic compound classified as an acetic acid derivative. The inclusion of diclofenac on lists of essential medicines reflects its widespread clinical recognition.

The classification as an NSAID signifies that this medicine is structurally engineered to modulate the body’s inflammatory response. Diclofenac is widely used for its established anti-inflammatory properties.

The Composition and Physical Form of Diclofenac 1%

The physical form of the medication is a smooth, homogeneous gel, specifically designed for topical administration to the skin, which is a key differentiator from orally administered tablets. This formulation is explicitly quantified by its 1% concentration, ensuring a defined amount of the active ingredient, diclofenac, within the preparation.

The base is typically a specialized hydrogel base, which includes components like purified water and alcohol that enhance the efficient percutaneous absorption of the diclofenac compound. This topical preparation is a single-active-ingredient product, engineered to focus its therapeutic effects through concentrated local delivery.

General Purpose: Anti-inflammatory and Analgesic Utility

The primary general purpose of Xenid 1% is to provide symptomatic relief through a powerful, chemically mediated anti-inflammatory effect and localized analgesic effect (pain relief). Topical diclofenac is used to treat pain and inflammation, providing a means for managing local tissue discomfort.

This utility is derived from the drug's mechanism of interfering with the production of prostaglandins, the signaling molecules that generate pain and inflammation. By delivering the compound via a topical gel, the medicine focuses its therapeutic effects on the soft tissues immediately beneath the application site, maximizing its local action for targeted relief.

Regulatory References

  1. World Health Organization Model List of Essential Medicines
  2. National Institutes of Health

What side effects are possible with Xenid 1%?

Possible Side Effects and Safety Information

The safety profile for Xenid 1% (Diclofenac Topical Gel) primarily involves localized reactions at the application site, alongside documented systemic risks required for its classification as a Non-steroidal Anti-inflammatory Drug (NSAID).

Documented Adverse Reactions

The most frequently observed adverse reactions are categorized under Skin and Subcutaneous Tissue Disorders. These effects are generally localized to the area of application.

Frequency Classification Documented Effects
Common (ge 1/100) Dermatitis (including contact dermatitis), Pruritus (itching), Erythema, Eczema.
Rare (ge 1/10,000) Dermatitis bullous.
Very Rare (<1/10,000) Photosensitivity reaction, Asthma, Angioneurotic edema.

Serious Systemic Safety Considerations

Official regulatory documents mandate the inclusion of serious systemic risks associated with NSAIDs, as low-level absorption of the active ingredient, diclofenac, cannot be excluded. Serious systemic events, though rare with topical use, are officially documented and include the potential for Serious Cardiovascular Thrombotic Events (such as Myocardial Infarction and Stroke) and severe Gastrointestinal Events (including bleeding, ulceration, and perforation).

Constraints and Special Populations

Safety notes identify conditions where particular caution or contraindication is required. The gel is contraindicated in patients who have experienced asthma or allergic-type reactions after taking aspirin or other NSAIDs. Use is officially avoided after 30 weeks gestation due to specific documented fetal risks. Additionally, the potential for systemic adverse events increases with application to large surface areas or over a prolonged period.

Interaction and Application Site Safety

Safety information specifies that concomitant use with oral NSAIDs may increase the incidence of adverse effects. Furthermore, the treated area must avoid exposure to natural or artificial sunlight due to the documented risk of photosensitivity reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Xenid 1% (Diclofenac 1% gel) primarily addresses the effects of accidental oral ingestion of large quantities, which may lead to systemic toxicity resembling that of systemic Non-steroidal Anti-inflammatory Drugs (NSAIDs). The documented risk of overdose is associated with the potential for systemic absorption of the active ingredient.

Documented Overdose Presentations

Official labeling describes overdose manifestations related to the Gastrointestinal (GI) system, the Central Nervous System (CNS), and major organ systems. The symptoms documented in regulatory sources include:

Clinical Manifestations Potential Severe Outcomes
Nausea, Vomiting, Diarrhea, Abdominal Pain Severe GI bleeding, Ulceration, Perforation
Headache, Dizziness, Somnolence, Tinnitus Acute renal failure, Liver damage, Seizures

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Official regulatory documents mandate that urgent emergency care is required when severe or life-threatening symptoms occur, such as vomiting blood, persistent pain, or signs of acute organ injury. The documented treatment strategy is strictly symptomatic and supportive treatment; no specific antidote is known for diclofenac overdose. Hospital monitoring of vital functions, as well as renal and hepatic function, is required. Elderly patients are noted to be at a greater risk for serious gastrointestinal events.

Therapeutic Uses of Xenid 1%

What Xenid 1% Treats: Main Uses and Benefits

Xenid 1% is a topical formulation that assists in managing local discomfort and inflammation. It is indicated for providing relief of pain associated with osteoarthritis of the knee, a condition characterized by joint discomfort and stiffness. The primary therapeutic application of this drug is to help alleviate the signs and symptoms of this condition in the treated areas.

In clinical contexts, Xenid 1% is a component of a comprehensive treatment plan designed to support patient mobility and enhance daily function for individuals with osteoarthritis of the knee. The mechanism of action is thought to be related to the local reduction of substances that contribute to the sensation of pain and inflammation within the joint area.

Usage of this topical treatment is intended to assist in achieving a meaningful improvement in local symptoms. Information regarding the indications and use of topical diclofenac is based on established clinical applications and product labeling.


Quick Facts

  • Condition Supported: Osteoarthritis of the knee.
  • Goal: Supports the management of local joint pain and inflammation.
  • Benefit: Intended to assist with signs and symptoms of the condition.
  • Patient Outcome: May support enhanced daily function and mobility.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Population Eligibility for Xenid 1%

Eligibility to use Xenid 1% (Diclofenac 1% Topical Gel) is strictly defined by regulatory documents, focusing on patient age, medical history, and physiological state.


Populations Contraindicated (Must Not Use)

Category Regulatory Statement
Allergy History Known hypersensitivity to diclofenac, aspirin, or other NSAIDs (Non-steroidal Anti-inflammatory Drugs).
Pregnancy Status Use starting at 30 weeks gestation or during the third trimester of pregnancy.
Surgical Setting In the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.
Pediatric Use Children and adolescents under 14 years of age (contraindicated or use not established).

Restricted and Conditional Use

Adults (18 years and older) are the generally approved population, but use is restricted in specific conditions:

  • Organ Function: Use is not recommended or requires caution in patients with severe renal impairment or severe heart failure.
  • Gastrointestinal Risk: Patients with a history of active peptic ulceration or gastrointestinal bleeding should use the product with caution.
  • Lactation: Use is not recommended while breastfeeding, and the gel must not be applied to the breasts.
  • Skin Integrity: The gel must not be applied to open wounds or areas affected by exfoliative dermatitis.

What should I know about interactions with other medicines?

Xenid 1% Interactions with other medicines and products

The interaction profile for Xenid 1% (diclofenac topical gel) is defined by its low systemic absorption, which limits the documented likelihood of many systemic interactions. However, official regulatory labeling outlines several potential drug-drug interactions and specific application restrictions.

Pharmacodynamic Interactions and Restrictions

Interacting Substance/Class Officially Documented Effect or Restriction
Oral NSAIDs & Aspirin Co-administration is not generally recommended due to the increased risk of systemic undesirable effects, specifically gastrointestinal bleeding (additive effect).
Anticoagulants Concomitant use increases the documented risk of bleeding.
Diuretics & ACE Inhibitors Caution is advised; long-term NSAID use can contribute to renal injury and diminish the antihypertensive effect.
Ciclosporin Use with caution due to the potential for nephrotoxicity from combined renal antiprostaglandin effects.

Exposure Modification

Official documents state that diclofenac may increase plasma concentrations of Lithium and Digoxin.

Local Site Combination Rules

Xenid 1% must not be used concomitantly with other topical products (including sunscreens, cosmetics, or other topical medications) on the same skin sites.

Population Considerations

Caution is required in patients with impaired renal function, heart failure, or liver dysfunction, as the risk of systemic adverse effects is heightened in these populations.

Mechanism of Action

The Pharmacodynamic Mechanism of Diclofenac

The mechanism of action for diclofenac is centered on its function as a competitive inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is highly active in inflamed tissues, where it catalyzes the synthesis of pro-inflammatory mediators. By physically blocking the enzyme's active site, the drug halts this synthesis, thereby altering the local tissue’s chemical dynamics.

The resulting molecular suppression directly impacts the Arachidonic Acid Cascade, causing a sharp reduction in key signaling molecules, notably Prostaglandin E2 (PGE2). This decrease in chemical signaling produces two primary physiological modulations: it limits the pathological increase in local vascular permeability, which modulates tissue fluid accumulation; and it suppresses the sensitization of peripheral nociceptors (sensory nerve endings), which results in a higher electrical threshold for nerve activation.

The action is peripherally restricted, meaning the mechanism’s efficacy is constrained by the need for the molecule to penetrate the skin barrier and achieve concentration in the subdermal structures to engage the COX-2 targets. The mechanism is thus characterized by localized pathway modulation.

Dosage and Administration Information

Xenid 1% is a topical preparation that is applied directly to the skin, which serves as the only approved route of administration for the 1% gel formulation. The usage is strictly governed by prescribed weight limits, which vary depending on the area of the body being treated.

For the lower extremities, such as the knee, ankle, or foot, the standard labeled dose is 4 grams (g) per joint per application, while joints in the upper extremities, like the hand or wrist, require 2 g per application. These specific amounts must be measured using the dosing card supplied with the product to ensure dose accuracy. The frequency of application is standardized to four times daily for the affected area.

The total daily application across all treated joints must not exceed 32 g. Application should be confined only to clean, intact skin that is free of cuts, rashes, or open wounds. Proper administration also requires specific post-application conditions to be met: the treated area should not be covered with clothing or gloves for at least 10 minutes, and the area must not be washed or showered for at least one (1) hour after the gel has been applied.

Regarding specific patient groups, the usual adult dosing regimen may be used for older adults. For children under 14 years of age, it is generally indicated that the safety and efficacy of the gel have not been established. If symptoms persist after seven days of continuous use, a professional medical review is recommended.

Recent Clinical Evidence

Xenid 1%: Recent Clinical Evidence

Clinical research into the use of Xenid 1% (a topical non-steroidal anti-inflammatory drug or NSAID) has focused on its potential role in managing pain and functional symptoms in specific localized conditions.

Evaluation of Chronic Pain Management

Research has explored whether the compound is associated with improvements in functional outcomes and reduction in pain in patients with chronic back pain.

  • Phase 3 Trial Findings: In a pivotal Phase 3 randomized controlled trial (RCT) concerning chronic low back pain, participants receiving the compound reported differences in average daily pain scores compared to placebo. These findings describe the observed effects of the compound in the trial. The studies utilized a specific dose of the compound.
  • Mechanism of Action: Mechanistic research was conducted alongside clinical studies. Studies explored whether the ability of the compound to modulate certain neurochemical pathways is associated with changes in pain perception.
  • Comparative Studies: Side-by-side analysis compared the observed outcomes of the compound to the currently available first-line treatments for the studied condition, with some trials reporting data related to gastrointestinal tolerability in addition to pain scores.

Short-Term and Long-Term Research

Studies have also examined the compound's application and effects across different timelines and patient groups:

  • Acute Pain Data: Some research related to short-term management, such as acute pain flare-ups, reported data related to the timing of changes in pain scores.
  • Long-term Effects and Subgroups: Long-term effects were assessed in the research, particularly in patient subgroups with existing comorbidities such as hypertension and type 2 diabetes. One study reported that the compound was not utilized in people with a history of severe liver issues.
  • Adjunctive Treatment Research: Studies also examined whether combining the compound with physical therapy was associated with changes in overall mobility compared to physical therapy alone.

Key Studies & References

  1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)
  2. A Systematic Review on NSAIDs and Tanezumab efficacy in Chronic Lower Back Pain (Reference to comparative studies)

Frequently Asked Questions (FAQ)

Common questions about Xenid 1% (FAQ)


Q: How quickly should someone expect Xenid 1% to start working?

According to the official product information, relief from the gel may take up to seven days to feel the full benefit. If pain relief is not experienced after seven days of continuous use, regulatory guidelines suggest that professional medical review may be appropriate.

Q: Is Xenid 1% known to cause any long-term effects?

Official documents describe that the medicine is generally utilized for the shortest duration that is consistent with treatment goals. Long-term use of the active ingredient, diclofenac, is known to increase the risk of serious systemic events, which include problems affecting the cardiovascular system and the gastrointestinal tract.

Q: Where can I find the official prescribing information for Xenid 1%?

Official prescribing information, known as the drug label, can be found on government websites that maintain drug listings. These resources include the National Library of Medicine’s DailyMed and the FDA’s website (Drugs@FDA).

Q: What does 'contraindication' mean when talking about Xenid 1%?

A contraindication is a specific condition or circumstance when the medicine is officially not recommended for use. According to official documents, this is because the potential for harm to the patient is considered to outweigh any benefit from the medicine.

Q: How does the drug stay in the body after using Xenid 1%?

The medicine is a topical preparation designed for a localized action, resulting in low systemic absorption. The small amount of the active ingredient that does enter the bloodstream is primarily processed by the liver and then eliminated from the body, mostly through urine.

Q: Is Xenid 1% a controlled substance?

No, Xenid 1% is not classified as a controlled substance. It belongs to the pharmacological class known as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: Can Xenid 1% cause changes in appetite or weight?

While rare with topical use, loss of appetite or unusual weight gain (due to fluid retention) are potential symptoms that may be associated with serious systemic adverse effects. These issues are listed in regulatory documents as signs of potential liver or heart complications.

Q: Is there a generic version of Xenid 1% available?

Yes, a generic version of the medicine's active ingredient, diclofenac sodium topical gel 1%, is available. The availability of generic alternatives is often indicated in official drug listings.

Q: How do I know if the condition I have is one that Xenid 1% treats?

Official documents state that the medicine is indicated to relieve pain related to osteoarthritis in specific joints. This generally includes joints that are easily treated by topical application, such as those in the hands, wrists, elbows, knees, ankles, and feet.

Q: What should I do if a friend or family member is experiencing unusual side effects from Xenid 1%?

Regulatory bodies, like the Food and Drug Administration (FDA), encourage patients and professionals to voluntarily report problems. Reporting of unusual side effects can be done through official programs such as the MedWatch Safety Information and Adverse Event Reporting Program.

Q: Can taking Xenid 1% affect my ability to drive or operate machinery?

Official product information notes that some potential systemic side effects of the active ingredient can rarely occur, such as dizziness or sleepiness. These effects may temporarily affect one's ability to safely drive or operate heavy machinery.

Q: Is Xenid 1% a new or established medication?

The active ingredient, diclofenac, is an established and widely recognized medicine globally. The specific topical gel formulation received its initial prescription approval in the U.S. around 2007 and later gained over-the-counter availability.

Q: Is Xenid 1% habit-forming or addictive?

No, as a Non-Steroidal Anti-Inflammatory Drug (NSAID), this medicine is not classified as habit-forming or addictive. This classification is noted in regulatory labeling.

Q: Does Xenid 1% have any known impact on fertility?

Official safety information indicates that NSAIDs like this medicine may impair female fertility. For women who are having difficulty conceiving, official documents indicate that the withdrawal of the medicine may be a consideration.

Q: How is the 'Interactions' section of the official label for Xenid 1% usually structured?

The official drug label typically structures the information for patients into distinct categories. These often include: Dosage and Administration, Warnings and Precautions, Drug Interactions, and information regarding Specific Populations.

Q: Does Xenid 1% have a patient information leaflet (PIL) and where can I find it?

Yes, government resources provide a Patient Information or Consumer Information section for the drug, often available in digital format. These can typically be found on websites like MedlinePlus or DailyMed.

Q: Can Xenid 1% affect sleep patterns?

Sleepiness is listed as a potential side effect of the medicine. Furthermore, trouble sleeping (insomnia) is also noted as a possible symptom related to systemic effects, such as a potential increase in blood pressure.

Q: What is the general duration of treatment described in the official guidance for Xenid 1%?

For the nonprescription gel, official guidance states that use should be limited to seven days unless otherwise directed by a healthcare professional. The duration for prescription use is determined individually by a healthcare provider.

Q: What are the general rules for stopping the use of Xenid 1%?

The official label suggests that if pain relief is not achieved after seven days, stopping the medicine and seeking professional review may be appropriate. General guidance is to use the medicine as directed, unless a healthcare professional advises otherwise.

How should Xenid 1% be stored and disposed of?

How to Store and Dispose of Xenid 1%

The storage and disposal of Xenid 1% (diclofenac sodium topical gel 1%) must strictly follow official regulatory guidelines to maintain product integrity and ensure public safety.


Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Do not freeze the gel. Keep the product in the original container and ensure it is tightly closed to protect it from moisture.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Discard unused or expired Xenid 1% strictly according to local regulations for pharmaceutical waste. It is required not to flush the product down the toilet or pour it into a drain unless instructed to do so by a regulated disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xenid 1% found in:

A-Z Index: